Atria Wealth Solutions Inc. Trims Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Atria Wealth Solutions Inc. cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,312 shares of the medical equipment provider’s stock after selling 334 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Zimmer Biomet were worth $1,620,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth approximately $25,000. Dunhill Financial LLC boosted its holdings in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Zimmer Biomet in the third quarter valued at $28,000. Brooklyn Investment Group acquired a new position in Zimmer Biomet in the third quarter valued at $35,000. Finally, Kentucky Trust Co purchased a new position in Zimmer Biomet during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $104.89 on Friday. The business has a 50 day moving average price of $105.86 and a two-hundred day moving average price of $107.45. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The firm has a market cap of $20.88 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 earnings per share. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is 21.57%.

Analysts Set New Price Targets

Several brokerages recently commented on ZBH. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Truist Financial restated a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Wells Fargo & Company lifted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Barclays dropped their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.